Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 4 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 4 of 10.)

DateHeadlineEventSource5-minTo close
Form 8-K JOHNSON & JOHNSON For: Oct 14SEC filing · Form 8-KSEC EDGAR-2.03%-1.42%
Johnson & Johnson Announces Intent to Separate Its Orthopaedics BusinessPress releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025Press releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales OutlookPress releaseBusiness Wire-2.03%-1.42%
Johnson & Johnson recommends shareholders reject “mini-tender” offer by TutanotaPress releaseBusiness Wire+0.73%+0.83%
Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP CongressPress releasePR Newswire+0.13%-0.54%
Johnson & Johnson to Participate in the UBS Global Healthcare ConferencePress releaseBusiness Wire+0.13%-0.54%
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pillPress releasePR Newswire-0.71%+1.81%
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact LensesPress releasePR Newswire-0.71%+1.81%
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitisPress releasePR Newswire-0.71%+1.81%
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation ConferencePress releaseBusiness Wire-0.71%+1.81%
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitorPress releasePR Newswire+0.21%+0.92%
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.42%+0.86%
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimenPress releasePR Newswire-0.44%-1.07%
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasisPress releasePR Newswire+0.61%+0.28%
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual MeetingPress releasePR Newswire+0.02%-0.37%
Sapient Insights Group Takes Stage at HR Tech Conference 2025Press releasePR Web+0.02%-0.37%
Form 8-K JOHNSON & JOHNSON For: Sep 08SEC filing · Form 8-KSEC EDGAR-0.26%-0.58%
Gulf War Veteran Partners with U.S. Navy Memorial to Remember the Fallen Heroes from WWI & WWIIPress releasePR Web-0.26%-0.58%
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treatedPress releasePR Newswire-0.34%-0.29%
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of DirectorsPress releaseBusiness Wire-0.26%-0.58%
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare ForumPress releaseBusiness Wire-0.26%-0.58%
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancerPress releasePR Newswire+0.06%+0.43%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.06%+0.43%
Johnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsPress releaseBusiness Wire-0.04%+0.43%
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) CongressPress releasePR Newswire+0.21%+0.28%
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart PumpPress releasePR Newswire+0.21%+0.28%
AMDR Applauds Federal Court Decision to Bar Johnson & Johnson’s Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the EnvironmentPress releaseBusiness Wire-0.67%-0.52%
Form N-PX JOHNSON & JOHNSON For: Jun 30SEC filing · Form N-PXSEC EDGAR+0.03%-0.10%
Lawsuit Alleges Big Pharma Hid Cancer Risk of Antipsychotic Drugs Marketed to Children, Elderly, and DisabledPress releasePR Web+0.82%+2.40%
"Big Pharma Playbook" Exposed in New Lawsuit Linking Antipsychotics to Breast CancerPress releasePR Web+0.13%-0.56%
Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferencePress releaseBusiness Wire+0.13%-0.72%
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder CasePress releaseBusiness Wire-0.13%-0.45%
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritisPress releasePR Newswire+0.06%—
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for MillionsPress releasePR Newswire+0.06%—
Wisner Baum Takes On Pharma Giants in Lawsuit Linking Widely Prescribed Antipsychotic Drugs to Breast CancerPress releasePR Web-0.03%-0.50%
Form 10-Q JOHNSON & JOHNSON For: Jun 29SEC filing · Form 10-QSEC EDGAR-0.18%-0.85%
Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025Press releasePR Newswire-0.19%+0.04%
Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare ConferencePress releaseBusiness Wire-0.18%-0.85%
Form 13F-HR JOHNSON & JOHNSON For: Jun 30SEC filing · Form 13F-HRSEC EDGAR-0.01%+0.85%
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasisPress releasePR Newswire-0.50%+0.30%
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancerPress releasePR Newswire-0.08%-0.62%
Dean Omar Branham Shirley Attorney Named Among Nation’s Top Future Legal LeadersPress releaseBusiness Wire+0.00%-0.59%
Form 8-K JOHNSON & JOHNSON For: Jul 16SEC filing · Form 8-KSEC EDGAR+1.26%+2.99%
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025Press releaseBusiness Wire+1.26%+2.99%
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 OutlookPress releaseBusiness Wire+1.26%+2.99%
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placeboPress releasePR Newswire+0.07%+0.85%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.01%+0.42%
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)Press releasePR Newswire+0.37%+0.81%
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc LawsuitPress releaseBusiness Wire+0.24%-0.69%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground